Amikin, Arikayce (amikacin) is a small molecule pharmaceutical. Amikacin was first approved as Amikin on 1982-01-01. It is used to treat acinetobacter infections, bacterial infections, burns, central nervous system infections, and endocarditis amongst others in the USA. It has been approved in Europe to treat respiratory tract infections. Amikacin sulfate's patents are valid until 2035-05-15 (FDA).
|Trade Name||Arikayce liposomal|
|Indication||acinetobacter infections, bacterial infections, burns, central nervous system infections, endocarditis, escherichia coli infections, infectious bone diseases, infectious skin diseases, intraabdominal infections, klebsiella infections, mycobacterium infections, proteus infections, pseudomonas infections, respiratory tract infections, serratia infections, soft tissue infections, staphylococcal infections, surgical wound infection, urinary tract infections|
|Drug Class||Antibiotics obtained from Streptomyces kanamyceticus (related to kanamycin)|